These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20048390)

  • 1. Measuring the right compound at the right time is not always easy.
    Brener SJ
    J Invasive Cardiol; 2010 Jan; 22(1):6-7. PubMed ID: 20048390
    [No Abstract]   [Full Text] [Related]  

  • 2. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
    Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
    J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
    Herrmann HC; Swierkosz TA; Kapoor S; Tardiff DC; DiBattiste PM; Hirshfeld JW; Klugherz BD; Kolansky DM; Magness K; Valettas N; Wilensky RL
    Am J Cardiol; 2002 Jun; 89(11):1293-7. PubMed ID: 12031731
    [No Abstract]   [Full Text] [Related]  

  • 4. Duration of action of GpIIb-IIIa antagonists.
    Johnson K
    Crit Care Nurse; 2000 Oct; 20(5):16. PubMed ID: 11878484
    [No Abstract]   [Full Text] [Related]  

  • 5. Abciximab, a novel platelet-blocking drug: pharmacology and nursing implications.
    Mayer DM; Docktor WJ
    Crit Care Nurse; 1998 Apr; 18(2):29-37. PubMed ID: 9708118
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
    Hézard N; Metz D; Garnotel R; Droullé C; Potron G; Nguyen P
    J Mal Vasc; 2000 Dec; 25(5):343-348. PubMed ID: 11148396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
    Coller BS; Anderson KM; Weisman HF
    Haemostasis; 1996 Oct; 26 Suppl 4():285-93. PubMed ID: 8979134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
    Med Lett Drugs Ther; 1998 Sep; 40(1035):89-90. PubMed ID: 9760948
    [No Abstract]   [Full Text] [Related]  

  • 12. Different benefits, different risks, equal cost.
    Colombo A
    Eur Heart J; 1999 Nov; 20(21):1531-2. PubMed ID: 10529320
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J; Rebello SS; Faul JD; Lucchesi BR
    Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 15. Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors?
    Bailey LA; Sistino JJ; Uber WE
    J Extra Corpor Technol; 2005 Mar; 37(1):43-7. PubMed ID: 15804156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirofiban counteracts pending myocardial infarction.
    Rasmanis G; Sylvén C
    J Intern Med; 2000 Oct; 248(4):349-52. PubMed ID: 11086647
    [No Abstract]   [Full Text] [Related]  

  • 17. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
    Lancet; 1997 May; 349(9063):1429-35. PubMed ID: 9164316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESPRIT in context: pharmacology matters!
    Tcheng JE; Strony J; Lorenz TJ; O'Shea JC
    Eur Heart J; 2001 Nov; 22(21):1965-7. PubMed ID: 11603901
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.